SciSparc Ltd. December 2024 Report: Key Insights on Pharmaceutical Spin-Off

Here are the key insights extracted from the provided section of the financial report for SciSparc Ltd.:

1. Filing Type: The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC.
2. Company Information:

• Name: SciSparc Ltd.
• Address: 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.

3. Report Date: The report is for the month of December 2024.
4. Commission File Number: 001-38041.
5. Content of Release: On December 16, 2024, SciSparc Ltd. issued a press release regarding the status of the spin-off of its advanced clinical stage pharmaceutical portfolio to a publicly traded company. This press release is included as Exhibit 99.1 to the report.
6. Incorporation by Reference: The report is incorporated into the Company’s registration statements on Form F-3 and Form S-8, indicating that the information contained within this report is considered part of those filings.
7. Signatory: The report is signed by Oz Adler, who holds the positions of Chief Executive Officer and Chief Financial Officer.
8. Date of Signature: December 17, 2024.

This report highlights an important strategic move by SciSparc Ltd. regarding the spin-off of its pharmaceutical portfolio, which could be significant for investors and stakeholders monitoring the company's growth and restructuring plans.